Market revenue in 2023 | USD 204.4 million |
Market revenue in 2030 | USD 528.5 million |
Growth rate | 14.5% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 54.26% in 2023. Horizon Databook has segmented the Asia Pacific mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
Countries like China, Japan, & India are experiencing significant growth in biopharmaceutical research and manufacturing, necessitating stringent quality control measures, including mycoplasma testing. Rising investment in R&D and government initiatives to boost biotech innovation has enhanced the need for reliable contamination detection methods.
In addition, the expansion of Contract Research and Manufacturing Organizations (CROs and CMOs) in the region has increased the demand for mycoplasma testing services. These organizations require robust testing to meet international quality standards and ensure the safety of their products.
The growing focus on biosimilars and cell-based therapies in the Asia Pacific market further underscores the importance of mycoplasma testing, as contamination can severely impact the efficacy and safety of these advanced therapeutics.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific mycoplasma testing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account